ASCO 2014

ASCO 2014

In this interview we discuss a bovine infectious agent, which may interact with carcinogens that arise during cooking or curing, and play a causative role in certain cancer.

Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.

In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.

Dr. Katz describes how he uses social media to learn more about patient perceptions of cancer, how to decide which social media to use, and drawbacks to using social media in a professional capacity.

Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.

Dr. Aisner discusses some of the key ways oncologists can work better with pathologists at their institutions.

In this interview, Dr. Hyman Muss discusses some of the barriers to providing high-quality care to geriatric cancer patients, including the barriers to diagnosis and treatment.


Subscribe to ASCO 2014 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.